BioCorRx Inc. (OTC: BICX), a developer of innovative treatment support programs for substance abuse and related disorders, along with its pharmaceutical subsidiary BioCorRx Pharmaceuticals Inc., has reported significant operational, clinical, intellectual property, and governance milestones in its third-quarter 2026 Form 10-Q filing. The company established new National Drug Codes (NDCs) under its own Labeler Code (85789) for all four branded LUCEMYRA® (lofexidine) and Authorized Generic (AG) SKUs, a move that positions the subsidiary to complete the commercial transition of the portfolio by year-end while maintaining uninterrupted market supply. LUCEMYRA® is an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults, and the commercial transition is expected to streamline distribution and potentially enhance revenue capture for BioCorRx.
In clinical development, BioCorRx Pharmaceuticals initiated and progressed a Phase 1 study of BICX104, an investigational biodegradable naltrexone implant, under the FDA’s 505(b)(2) pathway with support from the National Institute on Drug Abuse (NIDA). The study, titled “Safety and Pharmacokinetics Study of BICX104 With or Without Bupropion Compared to Vivitrol” (ClinicalTrials.gov Identifier: NCT07269873), aims to evaluate the safety and pharmacokinetics of the implant, which is designed to address adherence challenges associated with daily oral and monthly injectable therapies for opioid use disorder (OUD) and alcohol use disorder. If successful, BICX104 could offer a longer-acting treatment option, potentially improving outcomes for patients struggling with adherence.
The company also secured U.S. Patent No. 12,569,430 for a “Biodegradable Implant Including Naltrexone,” strengthening its intellectual property portfolio and providing protection for its implant technology. In governance, BioCorRx appointed Louis Lucido as Chair of the Board and added Richard J. Baum, former Acting White House Drug Policy Director, to its Strategic Advisory Board. These appointments bring additional expertise as the company navigates the commercial and regulatory landscape.
“2026 has been a transformative year of execution across both BioCorRx Inc. and our subsidiary, BioCorRx Pharmaceuticals Inc.,” said Lourdes Felix, CEO and CFO of BioCorRx Inc. “By establishing our own NDCs ahead of the year-end commercial transition of LUCEMYRA® and its Authorized Generic, initiating our Phase 1 study for BICX104, expanding our patent protection, and strengthening our Board and advisory leadership, we are building real momentum heading into 2027.”
The news is significant for stakeholders in the addiction treatment space, as opioid use disorder affects approximately 4.0 million people in the United States aged 12 or older, yet only 15.7% received medication treatment, according to the Substance Abuse and Mental Health Services Administration’s 2025 National Survey on Drug Use and Health. BioCorRx’s advancements could help expand access to effective treatments. Additionally, the company’s UnCraveRx® Weight Loss Program, a medication-assisted weight loss program, is part of its broader portfolio, and investors can find more information at www.uncraverx.com. For details on BioCorRx’s pipeline, visit www.BioCorRx.com. The company’s progress also comes amid a growing global obesity crisis; the World Health Organization (WHO) reports that approximately 940 million adults worldwide were living with obesity in 2024, and the World Obesity Federation’s World Obesity Atlas projects the global economic impact to exceed $4.3 trillion annually by 2035. While BICX104 has not been evaluated for weight management, naltrexone is a component of an FDA-approved combination therapy for chronic weight management, highlighting potential future applications. For full prescribing information on LUCEMYRA®, click Prescribing Information, and to report adverse reactions, visit www.fda.gov/medwatch.


